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Background: The percentage of time during which the patients have the INR within the target values (i.e. Time in
Therapeutic Range [TTR]) is a measure of anticoagulation quality with Vitamin K Antagonists (VKA). To evaluate the
quality of anticoagulation using TTR according to the Rosendaal method, we performed an observational,
retrospective study. We included all outpatients who attended the cardiology anticoagulation clinic of a Portuguese
hospital (2011–2013), whose target INR was 2.0-3.0.
Results: 377 VKA-treated patients were evaluated. Of these, 72.4% had non-valvular atrial fibrillation. Patients were
followed for a mean period of 471 days. The mean TTR was 60.3% (SD 19.3%) and 44.3% of the patients had a
mean TTR < 60%. Patients were at high risk of bleeding (INR > 4.5) and at high thrombotic risk (INR < 1.5) during,
respectively, 1.7% and 4.7% of the time.
Conclusions: Anticoagulation control needs to be improved. These results are informative for all stakeholders:
patients, health care professionals, and policymakers.
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Vitamin K Antagonists (VKA) such as warfarin, aceno-
coumarol and phenpromcom are widely prescribed oral
anticoagulant drugs. The main indications are atrial fibril-
lation (AF), valvular prosthesis, venous thromboembolism
and intracavitary thrombus. These drugs’ efficacy and
safety depends on International Normalized Ratio (INR)
monitoring. The absence of standard dosages of VKA
turns imperative to perform serial INR tests and make
dosages adjustments when the results are out of the range.
INR levels above and under pretended values are asso-
ciated to increased risk of hemorrhagic and thrombo-
embolic events, respectively [1,2].* Correspondence: dgcaldeira@hotmail.com
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unless otherwise stated.Time in therapeutic range (TTR) is a measure of qua-
lity of anticoagulation and lower values are related to
adverse events [3].
TTR knowledge is important to identify the current
standard of anticoagulation care and establish new goals.
Additionally TTR is an important input to determine
the cost-effectiveness of new oral anticoagulants [4].
The most comprehensive published data about TTR
in Portuguese patients comes from RE-LY study. This
trial included Portuguese patients and mean TTR was
61% [5,6].
TTR data retrieved from randomized controlled trials
may overestimate those from real world [7]. Therefore
we aimed to retrospectively review the charts of patients
from a single-center anticoagulation consultation in
order to estimate TTR.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Main characteristic of included patients
Characteristics Population (N = 377)
Age – years
Mean (SD) 71.0 (10.4)
Median (IQR) 72.0 (66–79)
Female sex – no. (%) 153 (40.6)
Previous stroke or transient ischemic
attack – no. (%)
56 (14.9)
Heart failure – no. (%) 160 (42.4)
Diabetes mellitus – no. (%) 101 (26.8)
Hypertension - no. (%) 253 (67.1)
Vascular Disease History – no. (%) 122 (32.4)
Indication for anticoagulation
Non-valvular AF 273 (72.4)
Valvular AF* 72 (19.1)
Venous thromboembolism 13 (3.4)
Others 19 (5.1)
CHA2DS2-VASc
Mean (SD) 3.58 (1.62)
Median (IQR) 3 (2–5)
*Mitral stenosis, severe aortic stenosis, severe mitral regurgitation, biologic
prosthetic valves, valve repair. AF: Atrial Fibrillation; IQR: Interquartile Range;
SD: Standard Deviation
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Study design and setting
We conducted a retrospective cohort study of patients
treated with vitamin K antagonists followed in Cardiology
Anticoagulation Clinic a Portuguese single-centre from
January 2011 to July 2013, in order to determine the TTR
of the centre. We obtained Institutional Board and Ethics
Committee approval for this study.
Participants, variables and statistical analysis
We identified all patients treated with vitamin K antago-
nists followed in the Outpatient Cardiology Anticoagula-
tion Clinic. Patients’ data were retrieved from a database
which contains the all INR records obtained in the visits.
All patients were submitted to nurse led INR checking
using CoaguCheck® XS system and follow-up was made
according to INR value, and hospital protocol or physi-
cians preferences.
For analysis, we included patients whose target INR
was between 2.0 and 3.0 (patients with INR targets bet-
ween 2.5 to 3.5, including patients with mechanical heart
valves were excluded). To better characterize the quality
of long-term anticoagulation all patients under 2 months
of follow-up tests or <6 INR tests were excluded [8]. We
have characterized the demographic and clinical charac-
teristics of the population. For each patient we evaluated
all available INR values to calculate the individual TTR
according to the Rosendaal method [9]. This method
uses linear interpolation to assign an INR value to each
day between successive observed INR values.
Patients were clustered into subgroups according to the
reason/indication for anticoagulation: non-valvular AF;
valvular AF (patients with mitral stenosis, severe aortic
stenosis, severe mitral regurgitation, biologic prosthetic
valves, valve repair); venous thromboembolic disease; and
others (including left ventricular dysfunction, intracavitary
thrombus, non-compaction cardiomyopathy).
The primary outcome was the TTR, a continuous out-
come. Secondary outcomes were: 1) TTR < 60%, a
marker of poor quality in the control of INR [3,10]; 2)
time under therapeutic range (INR < 2.0); 3) time over
therapeutic range (INR > 3.0); 4) time with increased
thrombotic risk (INR < 1.5); 5) time with increased
hemorrhagic risk (INR > 4.5).
All analyses were conducted using SPSS software
version 9.1. Statistical summary measures such as arith-
metic mean and median were used to characterize the
population. Standard deviation (SD) and interquartile
range were used to evaluate data dispersion. Multivariate
logistic regression analysis was performed to identify risk
factors for TTR < 60%, at a significance level of 0.05. Chi-
square test was performed for the comparison of dich-
otomic data across groups. One-way ANOVA was used
to evaluate differences between TTR across indications(more than 2 groups). The results were considered to be
statistically significant at a p-value <0.05.
Ethics
Hospital Garcia de Orta Institutional Board and Ethics
Committee have approved this project.
Results
We found 501 patients treated with VKA with target
INRs between 2.0 and 3.0, with their INR recorded in
the database between January 2011 and July 2013. About
377 patients had the minimum required follow-up/num-
ber of tests to meet the inclusion criteria.
The mean age was 71 years, and 59.4% of the patients
were male. Most of the patients had non-valvular AF
(72.4%), while valvular AF (19.1%) and venous thrombo-
embolic disease (3.4%) were less common. The popula-
tion’s average CHA2DS2-VASc was 3.58.
Patients were followed for a mean period of 471 days,
having performed on average 17 INR tests per year each
patient. The average time between two tests was 25.4 days.
Table 1 shows the main characteristic of the population.
The mean TTR was 60.3% (SD 19.3%) and the median
63% (interquartile range 47.9-74.8%). About 44.3% of the
patients evaluated have a mean TTR < 60%, and are at
increased risk of thrombotic and hemorrhagic events.
The female gender was the only characteristic that was
significantly associated to poor anticoagulation control
Figure 2 Histogram with relative frequencies of TTR values and
proportion of patients with TTR < 60%.
Figure 1 Time in therapeutic range (TTR) and time out of therapeutic range.
Caldeira et al. BMC Research Notes 2014, 7:891 Page 3 of 5
http://www.biomedcentral.com/1756-0500/7/891(TTR < 60%) in the multivariable regression analysis with
an odds ratio 1.73 and 95% confidence interval 1.14-2.62
(p = 0.01).
The average percentage of time that patients remained
above (INR > 3.0) and below the target INR (INR < 2.0)
was 16.5% and 23.2%, respectively. Patients were at high
risk of bleeding (INR > 4.5) 1.7% of the time, and at high
thrombotic risk (INR < 1.5) 4.7% of the follow-up period.
Figures 1 and 2 illustrate these results.
Non-valvular AF was the most prevalent indication for
anticoagulation. The mean CHA2DS2-VASc was 3.65
(SD 1.58). In this cluster of patients, the average TTR was
59.3% (SD 19.8%) and the median was 61.8% (interquartile
range 47.4-73.7%). These patients were on average 23.4%
of the time below therapeutic range (INR < 2.0), and
17.3% of the time over INR 3.0. The mean percentage of
time with high thrombotic risk (INR < 1.5) was 5.3%, and
1.7% of the time patients were at high risk of bleeding.
There were no significant differences in average TTR
between the different indications for VKA treatment
(p = 0.18). The proportion of patients with low anticoa-
gulation control also was not different across conditions
(p = 0.53). Table 2 shows the mean TTR and the propor-
tion of TTR < 60% according to the main indication for
anticoagulation.
Discussion
VKA have been shown to be effective in the treatment
and prevention of thromboembolic events, however they
possess many drug-drug and drug-food interactions, as
well as a narrow therapeutic window. Despite high num-
ber of studies in the field, much of the individual varia-
bility in response to warfarin therapy remains unexplained
and, therefore careful monitoring is required in order toreduce the risk of tromboembolic events and bleeding
complications. This process is costly and inconvenient for
many patients [11]. The quantification of TTR allows
characterization and of anticoagulation control quality.
According to our study, the TTR of this population of
anticoagulated Portuguese patients was 60.3% during a
mean follow-up of 1.3 years. Forty-four percent of this
population had a TTR < 60%. This means that an im-
portant proportion of patients are at increased risk of
major adverse events [3,10,12].
The results show an inadequate control of anticoagula-
tion from a global point of view [13,14]. Additionally,
the identification of the female gender as a predictor of
low TTR goes in line with the recent SAMe-TT2R 2 that
identifies women (Sex – female; S in the acronym) as
Table 2 Mean Time in Therapeutic Range (TTR) according to main indication for anticoagulation
Population Mean TTR (SD) TTR < 60% (%) Patients Average follow-up (years)
Non-valvular AF 59.3% (19.7%) 128 (46.7%) 274 1.27
Valvular AF 64.0% (18.6%) 29 (40.3%) 72 1.44
Venous thromboembolism 54.6% (24.4%) 5 (38.5%) 13 1.18
AF: Atrial Fibrillation; SD: Standard Deviation; TTR: Time In Therapeutic Range.
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VKA [15].
Recent large trials with new oral anticoagulants in AF
provided further data about world-wide quality of anticoa-
gulation control. In ROCKET-AF the mean TTR was
55.2% (63% in Western Europe, 64% in North America)
[16], and the median TTR was 66% in ARISTOTLE
[17]. The RE-LY study had a median TTR of 67.2% and
presented TTR data according to countries, including
Portugal. The benchmark countries were Sweden, Finland,
and Australia with TTR values of 77% (Sweden) and 74%
(Finland and Australia) [6]. The results obtained in our
study are similar to those of the RE-LY study for Portugal
(61%), and are overall in accordance to those reported in
the literature [7,18].
In our study we calculated individual patient TTR
using a longitudinal linear extrapolation of INR values
through a method proposed by Rosendaal as it is more
time sensitive than other methods (takes into account
the number of days within the range) [19].
The experience of other national centres about the
quality of anticoagulation control reports data of INR
tests within pretended ranges, rather than longitudinal
TTR method. In an anticoagulation clinic 1067 INR con-
trols were performed in two months in 687 patients.
About 71% of the tests were within the range [20]. An-
other single centre experience of INR telemonitoring
showed that 83% of the tests were within the range [21].
Applying our data to those retrieved from randomized
controlled trial, in centres with TTR of 61%, new oral
anticoagulants tend to be safer and/or more effective
than VKA. In RE-LY, all dosages (110 mg and 150 mg
bid) had a significant lower risk of intracranial bleeding,
with a similar risk major bleeding, while in the preven-
tion of thromboembolic events only the dosage of
150 mg showed a significant risk reduction compared to
warfarin. The efficacy of rivaroxaban was not statistically
different from warfarin but there was a trend towards
rivaroxaban in the prevention of thromboembolic com-
plications (HR 0.70; IC95% 0.48-1.03). Apixaban was
safer in terms of major bleeding with an efficacy likely to
be better than warfarin (HR 0.73; IC95% 0.53-1.00).
Limitations
The main limitation of this study was that it was a retro-
spective, non-randomised cohort of patients anticoagulatedwith VKA followed in the Cardiology Anticoagulation
Consultation of a single-center. However this is still, to the
best of our knowledge, the first study evaluating the quality
of anticoagulation in Portugal with Rosendaal TTR.
Patients with non-valvular AF with stable therapeutic
INR values are usually proposed for discharge to primary
care follow-up. The data here presented does not ac-
count for INR values registered in other facilities, such
as in the emergency room or during hospitalizations.
These reasons may limit the conclusions of this study.
We did not focus on other patients with very high
thrombotic risk such as those carrying mechanical heart
valves (because INR target is 2.5-3.5). So the data here
presented cannot be extrapolated to such subgroups.
We used CHA2DS2-VASc score all patients, neverthe-
less we recognize that the use of such tool in valvular
AF or in VTE may not be adequate. This score identifies
prevalent risk factors for thromboembolism and we used
to describe the population without performing any ana-
lysis on this basis.
Conclusions
The average TTR of this center was 60.3%. An impor-
tant proportion of patients was at high risk of events
(TTR < 60%). At our center, anticoagulation control
should be improved. When out of therapeutic range, pa-
tients were more commonly prone to prothrombotic
risk due to the higher percentage of time with INR < 2.0.
These results are informative for all stakeholders: pa-
tients, health care professionals, and policymakers.
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